Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study
Clinical Transplantation · 2026-07 · 40 (7)
DOI: 10.1111/ctr.70617 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 08.07.2026. Verfasst von Paolo Randone und 10 weiteren Autor:innen. Beteiligte Einrichtung: Renal Transplant Center "A. Vercellone", Nephrology, Dialysis and Renal Transplant Division, Department of Medical Sciences, "Città Della Salute e de…. Hauptthemen laut MEDLINE: Kidney Transplantation, Glycine, Isoquinolines, Anemia. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Turin, Università degli Studi di Torino.
Abstract (Originalsprache)
Background
Roxadustat is an oral hypoxia‐inducible factor prolyl‐hydroxylase inhibitor. Recent studies have shown no inferiority of roxadustat compared to erythropoietin in chronic kidney disease and in post‐transplant patients. We evaluated roxadustat versus erythropoiesis‐stimulating agents (ESAs) in very early posttransplant patients.
Methods
We performed a retrospective analysis of the clinical course and laboratory changes in posttransplant patients treated with roxadustat (16 patients) or a high‐dose erythropoiesis‐stimulating agent (ESA) (16 patients) for anemia between March and September 2025. We compared haemoglobin, creatinine, lipid levels, and iron status. The therapy was started after the kidney transplant, respectively, after a median of 3.5 and two days. Every patient was followed up at two weeks, one month, two months, and three months.
Results
Patients treated with roxadustat showed a significantly greater and faster increase in Hb levels at 2 weeks ( p = 0.047) than the ESA group. After 2 weeks, we observed a significant difference in the need for blood transfusions between the groups ( p = 0.029; 18.8% in the roxadustat group vs. 62.5% in the ESA group). No significant differences were observed in iron or inflammation status during the study. The roxadustat group achieved a significantly better lipid profile after one month ( p < 0.05 for cholesterol and LDL). During the follow‐up, no adverse events related to roxadustat were reported.
Conclusion
Administration of oral roxadustat in very early post‐transplant patients is effective and safe, rapidly improving anemia and reducing the need for transfusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Transplant Center "A. Vercellone", Nephrology, Dialysis and Renal Transplant Division, Department of Medical Sciences, "Città Della Salute e della Scienza" Hospital, University of Turin, Turin, Italy.
ORCID-Profile: Luigi Biancone
Förderung
- University of Turin
- Università degli Studi di Torino
Zitieren
APA
Randone, P., Valenza, L., Mella, A., Fop, F., Dolla, C., Gallo, E., Manzione, A. M., Mingozzi, S., Tarragoni, R., Sanna, E., & Biancone, L. (2026). Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study. Clinical Transplantation, 40(7). https://doi.org/10.1111/ctr.70617
Vancouver
Randone P, Valenza L, Mella A, Fop F, Dolla C, Gallo E, et al. Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study. Clinical Transplantation. 2026;40(7). doi:10.1111/ctr.70617
BibTeX
@article{Randone2026,
author = {Randone, Paolo and Valenza, Laura and Mella, Alberto and Fop, Fabrizio and Dolla, Caterina and Gallo, Ester and Manzione, Ana Maria and Mingozzi, Silvia and Tarragoni, Rita and Sanna, Enrico and Biancone, Luigi},
title = {Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {7},
doi = {10.1111/ctr.70617}
}
EUVIMED